MedTrace Logo

Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers

NCT01600898 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2021-01-13

No results posted yet for this study

Summary

In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers. This study is designed to:

* determine predictive factors (biological, functional, radiological and hemodynamic) of development of PAH
* monitor these subjects' clinical, functional, biological, echocardiographic and hemodynamic characteristics
* assess the risk of occurrence of PAH
* screen patients with PAH at an early stage of disease and offer them an early management
* constitute a collection of biological samples (0, 12, 24 months follow-up) of asymptomatic BMPR2 mutation carriers.

Conditions

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • David Montani, Md, PhD · Assistance-Publique Hôpitaux de Paris, Hôpital Bicêtre, Service de pneumologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01600898 on ClinicalTrials.gov